NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Zusduri demonstrated a 72.2% 24-month response durability in LG-IR-NMIBC patients, leading to FDA approval as a non-surgical treatment option. The ENVISION trial enrolled 240 patients, focusing on ...
Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 ...
Graphical comparison of bladder augmentation surgery using either ileum (top) or a cell-seeded, biodegradable scaffold (bottom). MSCs and HSPCs represent different types of stem cells found in the ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the ...
Wellbeing Magazine on MSN
Patient monitoring devices in general practice: A practical guide for GP clinics
Accurate patient monitoring is not an optional extra in general practice. It is a fundamental part of the clinical encounter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results